Proteinuria Management in Hypertension and Diabetes

Initial Pharmacologic Approach

• The American Diabetes Association recommends starting an ACE inhibitor or ARB immediately and uptitrating to the maximally tolerated dose as first-line therapy for patients with hypertension, diabetes, and proteinuria 1, 2
• For patients with albuminuria ≥30 mg/g, ACE inhibitors or ARBs are mandatory first-line therapy to reduce the risk of progressive kidney disease and provide cardiovascular protection 1

Blood Pressure Targets

• The American Diabetes Association recommends targeting blood pressure <130/80 mmHg in patients with diabetes and proteinuria 1, 3
• For patients with glomerular disease and proteinuria, aim for systolic blood pressure of 120-130 mmHg when achievable 4, 5

Medication Titration Strategy

• Uptitrate the ACE inhibitor or ARB to the maximum tolerated or allowed daily dose before adding additional agents 4, 6, 7
• Do not stop ACE inhibitor/ARB therapy with modest and stable increases in serum creatinine (up to 30%) 7

Second-Line Agents

• Add a thiazide-like diuretic or dihydropyridine calcium channel blocker if blood pressure targets are not achieved with maximally dosed ACE inhibitor/ARB 1, 2, 3
• Thiazide-like diuretics are preferred over thiazides due to superior cardiovascular outcomes data 1

Resistant Hypertension Management

• For patients not achieving blood pressure targets on three medications (including a diuretic), add a mineralocorticoid receptor antagonist 1, 8, 3
• Ensure the three-drug regimen includes an ACE inhibitor/ARB, calcium channel blocker, and thiazide-like diuretic before diagnosing resistant hypertension 3

Critical Monitoring Requirements

• Monitor serum creatinine and potassium 7-14 days after initiating or adjusting ACE inhibitor/ARB doses, then at least annually 1, 9, 3
• Use potassium-wasting diuretics and/or potassium-binding agents to manage hyperkalemia and allow continuation of RAS blockade 4, 6, 5, 7, 10

Lifestyle Modifications

• Implement comprehensive lifestyle changes including sodium restriction to <2,300 mg/day (ideally <2,000 mg/day), weight normalization, and DASH-style eating pattern 4, 1, 6, 5, 7, 10, 3
• Restrict dietary sodium to <2.0 g/day (<90 mmol/day) for optimal blood pressure and proteinuria control 4, 6, 5, 7, 10

Proteinuria Goals

• Target proteinuria reduction to <1 g/day, though goals vary by underlying disease process 4, 6, 5

Important Contraindications and Precautions

• ACE inhibitors, ARBs, and mineralocorticoid receptor antagonists are contraindicated in pregnancy and should be avoided in sexually active individuals of childbearing potential not using reliable contraception 1
• Avoid starting ACE inhibitors/ARBs in patients presenting with abrupt onset nephrotic syndrome, as these drugs can cause acute kidney injury, especially in minimal change disease 7, 10

Additional Cardiovascular Risk Management

• Initiate statin therapy for hyperlipidemia management, particularly in patients with additional cardiovascular risk factors 4, 6, 5, 7
• Target LDL-C <55 mg/dL with at least 50% reduction in patients with type 2 diabetes at very high cardiovascular risk 11